Figure 1.
SEAIR model. S, E, A, I, R corresponds to susceptible, exposed, asymptomatic, infected, and recovered populations.
Figure 1.
SEAIR model. S, E, A, I, R corresponds to susceptible, exposed, asymptomatic, infected, and recovered populations.
Figure 2.
Example of a solution representation for a problem with five subgroups, two periods, and 100 vaccines per period.
Figure 2.
Example of a solution representation for a problem with five subgroups, two periods, and 100 vaccines per period.
Figure 3.
Example of newly infected persons per day data and SEAIR adjusted curve in Belgium. Second wave.
Figure 3.
Example of newly infected persons per day data and SEAIR adjusted curve in Belgium. Second wave.
Figure 4.
Comparison of newly infected people between SEAIR model and COVID-19 tests in Austria. Second wave.
Figure 4.
Comparison of newly infected people between SEAIR model and COVID-19 tests in Austria. Second wave.
Figure 5.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Austria. Second wave.
Figure 5.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Austria. Second wave.
Figure 6.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Austria’s second wave after applying the best vaccination plan found.
Figure 6.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Austria’s second wave after applying the best vaccination plan found.
Figure 7.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Austria’s second wave after applying the best vaccination plan found.
Figure 7.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Austria’s second wave after applying the best vaccination plan found.
Figure 8.
Plots of susceptible, exposed, asymptomatic, infected, recovered, and newly infected individuals per day for each region of the SEAIR model with the best vaccination plan found.
Figure 8.
Plots of susceptible, exposed, asymptomatic, infected, recovered, and newly infected individuals per day for each region of the SEAIR model with the best vaccination plan found.
Figure 9.
Comparison of newly infected people between SEAIR model and COVID-19 tests in Belgium. Second wave.
Figure 9.
Comparison of newly infected people between SEAIR model and COVID-19 tests in Belgium. Second wave.
Figure 10.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Belgium. Second wave.
Figure 10.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Belgium. Second wave.
Figure 11.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Belgium’s second wave after applying the best vaccination plan found.
Figure 11.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Belgium’s second wave after applying the best vaccination plan found.
Figure 12.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Belgium’s second wave after applying the best vaccination plan found.
Figure 12.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Belgium’s second wave after applying the best vaccination plan found.
Figure 13.
Plots of susceptible, exposed, asymptomatic, infected, recovered, and newly infected individuals per day for each region of the SEAIR model with the best vaccination plan found.
Figure 13.
Plots of susceptible, exposed, asymptomatic, infected, recovered, and newly infected individuals per day for each region of the SEAIR model with the best vaccination plan found.
Figure 14.
Comparison of newly infected people between SEAIR model and COVID-19 tests in Denmark’s second wave.
Figure 14.
Comparison of newly infected people between SEAIR model and COVID-19 tests in Denmark’s second wave.
Figure 15.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Denmark’s second wave.
Figure 15.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Denmark’s second wave.
Figure 16.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Denmark’s second wave after applying the best vaccination plan found.
Figure 16.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Denmark’s second wave after applying the best vaccination plan found.
Figure 17.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Denmark’s second wave after applying the best vaccination plan found.
Figure 17.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Denmark’s second wave after applying the best vaccination plan found.
Figure 18.
Plots of susceptible, exposed, asymptomatic, infected, recovered, and newly infected individuals per day for each region of the SEAIR model with the best vaccination plan found.
Figure 18.
Plots of susceptible, exposed, asymptomatic, infected, recovered, and newly infected individuals per day for each region of the SEAIR model with the best vaccination plan found.
Figure 19.
Comparison of newly infected people between SEAIR Model and COVID-19 tests in Chile. First and second wave.
Figure 19.
Comparison of newly infected people between SEAIR Model and COVID-19 tests in Chile. First and second wave.
Figure 20.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Chile. First and second wave.
Figure 20.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Chile. First and second wave.
Figure 21.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Chile’s second wave after applying the best vaccination plan found.
Figure 21.
Comparison of cumulative infected people between SEAIR model and COVID-19 tests in Chile’s second wave after applying the best vaccination plan found.
Figure 22.
Comparison of cumulative infected people between the SEAIR model and COVID-19 tests in Chile’s second wave after applying the best vaccination plan found.
Figure 22.
Comparison of cumulative infected people between the SEAIR model and COVID-19 tests in Chile’s second wave after applying the best vaccination plan found.
Figure 23.
Susceptible, exposed, asymptomatic, infected, recovered, and newly infected individuals per day for each region of the SEAIR model with the best vaccination plan found.
Figure 23.
Susceptible, exposed, asymptomatic, infected, recovered, and newly infected individuals per day for each region of the SEAIR model with the best vaccination plan found.
Table 1.
Parameter values ranges based on estimated values from CDC and CEBM.
Table 1.
Parameter values ranges based on estimated values from CDC and CEBM.
Parameter | Minimum | Value | Average | Value | Maximum | Value |
---|
| 2 days | 0.5 | 5–6 days | 0.2 | 14 days | 0.07 |
| 12 days | 0.08 | 2 weeks | 0.07 | 6 weeks | 0.024 |
| 10% | 0.1 | 40% | 0.5 | 70% | 0.7 |
| 5% | 0.05 | 30% | 0.3 | 80% | 0.8 |
Initial | 2 | 2 | 3 | 3 | 6 | 6 |
Table 2.
Average time and maximum infected population obtained per country file for different probabilities of the movements. The best value per file is highlighted in bold.
Table 2.
Average time and maximum infected population obtained per country file for different probabilities of the movements. The best value per file is highlighted in bold.
Input Data | Configuration | Average Time [s] | Average Maximum Infected |
---|
Austria | | 139 | 30,392.8 ± 416 |
| 146 | 30,169.8 ± 370 |
| 170 | 29,426.7 ± 401 |
| 178 | 29,430.8 ± 450 |
| 184 | 29,138.2 ± 345 |
| 200 | 28,968.2 ± 321 |
Belgium | | 233 | 166,553.210 ± 119 |
| 240 | 166,464.9 ± 165 |
| 286 | 166,157.8 ± 238 |
| 292 | 166,156.1 ± 303 |
| 308 | 166,045.5 ± 296 |
| 319 | 165,623.0 ± 309 |
Denmark | | 54 | 3202.901 ± 25 |
| 49 | 3189.4 ± 25 |
| 48 | 3156.8 ± 13 |
| 49 | 3157.3 ± 10 |
| 49 | 3155.7 ± 13 |
| 52 | 3149.9 ± 6 |
Chile | | 391 | 125,554.613 ± 78 |
| 439 | 125,601.3 ± 122 |
| 595 | 125,799.9 ± 351 |
| 617 | 125,966.4 ± 230 |
| 643 | 126,038.0 ± 272 |
| 620 | 126,205.0 ± 241 |
Table 3.
Wilcoxon comparison for different probabilities of the movements results. Asterisks indicate each comparison where a statistical difference with 95% confidence was found.
Table 3.
Wilcoxon comparison for different probabilities of the movements results. Asterisks indicate each comparison where a statistical difference with 95% confidence was found.
| Austria | Belgium | Denmark | Chile |
---|
| | | | | | | | | | | | | | | | | | | | | | | | |
| - | - | * | * | * | * | - | - | * | * | * | * | - | - | * | * | * | * | - | - | * | * | * | * |
| | - | * | * | * | * | | - | * | * | * | * | | - | * | * | * | * | | - | * | * | * | * |
| | | - | - | * | * | | | - | - | - | * | | | - | * | * | * | | | - | - | - | * |
| | | | - | * | * | | | | - | - | * | | | | - | - | * | | | | - | - | * |
| | | | | - | * | | | | | - | * | | | | | - | * | | | | | - | * |
| | | | | | - | | | | | | - | | | | | | - | | | | | | - |
Table 4.
Average time and maximum infected population obtained per country file for different initialization procedures. The best value per file is highlighted in bold.
Table 4.
Average time and maximum infected population obtained per country file for different initialization procedures. The best value per file is highlighted in bold.
Input Data | Configuration | Average Time [s] | Average Maximum Infected |
---|
Austria | All to One | 134 | 28,657.059 ± 0 |
Inner Interaction | 170 | 29,426.7 ± 401 |
Outer Interaction | 165 | 29,359.6 ± 400 |
Mixed Interaction | 155 | 29,138.2 ± 313 |
Equity | 180 | 29,428.9 ± 544 |
Belgium | All to One | 237 | 165,184.1 ± 0 |
Inner Interaction | 286 | 166,157.8 ± 238 |
Outer Interaction | 295 | 166,177.1 ± 283 |
Mixed Interaction | 290 | 165,869.9 ± 295 |
Equity | 312 | 166,162.5 ± 313 |
Denmark | All to One | 33 | 3146.7 ± 0 |
Inner Interaction | 48 | 3156.8 ± 13 |
Outer Interaction | 48 | 3158.2 ± 16 |
Mixed Interaction | 45 | 3152.0 ± 7 |
Equity | 48 | 3156.0 ± 10 |
Chile | All to One | 423 | 126,665.0 ± 0 |
Inner Interaction | 595 | 125,799.9 ± 351 |
Outer Interaction | 642 | 125,773.9 ± 302 |
Mixed Interaction | 606 | 126,135.6 ± 222 |
Equity | 612 | 125,897.7 ± 193 |
Table 5.
Wilcoxon comparison for different initialization procedures results. Asterisks indicate each comparison in which a statistical difference with 95% confidence was found.
Table 5.
Wilcoxon comparison for different initialization procedures results. Asterisks indicate each comparison in which a statistical difference with 95% confidence was found.
| Austria | Belgium | Denmark | Chile |
---|
| | | | | | | | | | | | | | | | | | | | |
| - | * | - | * | - | - | * | - | * | - | - | * | - | * | - | - | * | - | - | - |
| | - | * | * | * | | - | * | * | * | | - | * | * | * | | - | * | * | * |
| | | - | * | - | | | - | * | - | | | - | * | - | | | - | - | - |
| | | | - | * | | | | - | * | | | | - | * | | | | - | * |
| | | | | - | | | | | - | | | | | - | | | | | - |
Table 6.
Average time, maximum infected as MI, total infected as TI, and average function value per problem for different weighing in the evaluation function. The best time per file is highlighted in bold, and the best objective function value is shown in bold.
Table 6.
Average time, maximum infected as MI, total infected as TI, and average function value per problem for different weighing in the evaluation function. The best time per file is highlighted in bold, and the best objective function value is shown in bold.
Input data | Percentage of MI | Percentage of TI | Average Time [s] | Average Function Value | Average MI | Average TI |
---|
Austria | | | 133 | 28,657.0 | 28,657.0 | 48,154.5 |
| | 142 | 32,556.5 | 28,657.1 | 48,154.5 |
| | 137 | 38,405.8 | 28,657.1 | 48,154.5 |
| | 136 | 44,255.0 | 28,657.1 | 48,154.5 |
| | 149 | 48,154.5 | 28,657.1 | 48,154.5 |
Belgium | | | 237 | 165,184.1 | 165,184.1 | 487,775.6 |
| | 230 | 229,702.4 | 165,184.1 | 487,775.6 |
| | 235 | 326,479.8 | 165,184.1 | 487,775.6 |
| | 246 | 423,257.3 | 165,184.1 | 487,775.6 |
| | 241 | 487,775.6 | 165,184.1 | 487,775.6 |
Denmark | | | 33 | 3146.6 | 3146.6 | 6304.9 |
| | 35 | 3778.3 | 3146.7 | 6305.0 |
| | 36 | 4725.8 | 3146.7 | 6305.0 |
| | 36 | 5673.3 | 3146.7 | 6305.0 |
| | 33 | 6305.0 | 3146.6 | 6305.0 |
Chile | | | 423 | 126,665.0 | 126,665.0 | 324,734.1 |
| | 469 | 166,278.8 | 126,665.0 | 324,734.2 |
| | 460 | 225,699.6 | 126,665.0 | 324,734.2 |
| | 472 | 285,120.3 | 126,665.0 | 324,734.2 |
| | 485 | 324,734.1 | 126,665.0 | 324,734.1 |
Table 7.
Vaccines corresponding to the most vaccinated subgroups of the best vaccination plan obtained from SEAIRV model.
Table 7.
Vaccines corresponding to the most vaccinated subgroups of the best vaccination plan obtained from SEAIRV model.
| Vienna | Lower Austria | Styria | Tyrol | Salzburg | Vorarlberg |
---|
1st Vac. | 0 | 0 | 0 | 0 | 0 | 250,000 |
2nd Vac. | 80,493 | 4436 | 767 | 3231 | 5138 | 111,973 |
3rd Vac. | 3040 | 89,984 | 48,955 | 8555 | 82,470 | 139 |
4th Vac. | 0 | 136,992 | 23,061 | 51,267 | 0 | 0 |
5th Vac. | 0 | 18,918 | 132,868 | 71,411 | 0 | 0 |
Table 8.
Comparison table of infections with and without vaccination.
Table 8.
Comparison table of infections with and without vaccination.
| With Best Vaccination | Without Vaccination | Decrease Percentage |
---|
Total Infected | 245,494.840 | 306,179.115 | |
Maximum Infected and Asymptomatic | 70,114.634 | 85,351.480 | |
Maximum Infected | 68,085.025 | 82,903.757 | |
Maximum Newly Infected per Day | 4648.093 | 5645.949 | |
Table 9.
Vaccines corresponding to the most vaccinated subdivision of the best vaccination plan obtained from SEAIRV model.
Table 9.
Vaccines corresponding to the most vaccinated subdivision of the best vaccination plan obtained from SEAIRV model.
| Flemish Brabant | Antwerp | Liège | Walloon Brabant | Limburg | Namur |
---|
1st Vac. | 0 | 0 | 300,000 | 0 | 0 | 0 |
2nd Vac. | 91,507 | 47,449 | 0 | 20,133 | 4935 | 10,067 |
3rd Vac. | 59,017 | 29,817 | 16 | 13,188 | 83,452 | 30,376 |
4th Vac. | 0 | 0 | 0 | 300,000 | 0 | 0 |
5th Vac. | 1380 | 2656 | 0 | 62,231 | 0 | 225,805 |
Table 10.
Comparison table of infections with and without vaccination.
Table 10.
Comparison table of infections with and without vaccination.
| With Best Vaccination | Without Vaccination | Decrease Percentage |
---|
Total Infected | 502,679.096 | 495,482.655 | |
Maximum Infected and Asymptomatic | 155,287.904 | 169,063.317 | |
Maximum Infected | 148,644.350 | 161,669.909 | |
Maximum Newly Infected per Day | 15,914.796 | 18,116.113 | |
Table 11.
Best vaccination plan obtained from SEAIRV model.
Table 11.
Best vaccination plan obtained from SEAIRV model.
| Hovedstaden | Midtjylland | Syddanmark | Sjælland | Nordjylland |
---|
1st Vac. | 0 | 0 | 0 | 0 | 250,000 |
2nd Vac. | 168,060 | 56,363 | 419 | 25,158 | 0 |
3rd Vac. | 14,360 | 0 | 196,157 | 39,483 | 0 |
4th Vac. | 179,988 | 15,631 | 32,347 | 22,034 | 0 |
5th Vac. | 13,176 | 124,383 | 41,548 | 70,893 | 0 |
Table 12.
Comparison table of infections with and without vaccination.
Table 12.
Comparison table of infections with and without vaccination.
| With Best Vaccination | Without Vaccination | Decrease Percentage |
---|
Total Infected | 74,113.695 | 218,113.191 | |
Maximum Infected and Asymptomatic | 26,976.820 | 49,953.341 | |
Maximum Infected | 22,582.891 | 43,118.680 | |
Maximum Newly Infected per Day | 2141.13 | 3577.559 | |
Table 13.
Vaccines corresponding to the most vaccinated subdivision of the best vaccination plan obtained from SEAIRV model.
Table 13.
Vaccines corresponding to the most vaccinated subdivision of the best vaccination plan obtained from SEAIRV model.
| Metropolitan | Biobío | Los Lagos | Ñuble | Los Ríos | Arica y Parinacota |
---|
1st Vac. | 0 | 0 | 500,000 | 0 | 0 | 0 |
2nd Vac. | 292,324 | 65,504 | 537 | 186 | 2084 | 113 |
3rd Vac. | 410,403 | 0 | 0 | 0 | 0 | 0 |
4th Vac. | 0 | 52,199 | 33,2241 | 94,743 | 0 | 0 |
5th Vac. | 0 | 0 | 0 | 32,033 | 374,274 | 93,397 |
Table 14.
Comparison table of infections with and without vaccination.
Table 14.
Comparison table of infections with and without vaccination.
| With Best Vaccination | Without Vaccination | Decrease Percentage |
---|
Total Infected | 840,096.735 | 983,040.848 | |
Maximum Infected and Asymptomatic | 111,306.477 | 129,594.850 | |
Maximum Infected | 101,152.092 | 117,983.213 | |
Maximum Newly Infected per Day | 6465.033 | 7410.361 | |